379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study

医学 内科学 耐受性 肿瘤科 不利影响 胃肠病学
作者
Peter Schmid,Piotr J. Wysocki,X. Cynthia,Y.H. Park,Renan Fernandes,Simon Lord,Richard D. Baird,Catherine Prady,Kyung Hae Jung,Jamil Asselah,Robert Huisden,Ross Stewart,K. Heider,Petra Vuković,Neelima Denduluri,Zbigniew Nowecki
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:34: S337-S337 被引量:44
标识
DOI:10.1016/j.annonc.2023.09.556
摘要

BEGONIA (NCT03742102) is an ongoing 2-part, open-label platform study in 1L a/mTNBC, evaluating D, an anti–PD-L1 antibody, plus novel therapies, including Dato-DXd, an antibody-drug conjugate made of a anti-TROP2 antibody covalently linked via a cleavable linker to a topoisomerase I inhibitor payload. Early data from BEGONIA Arm 7, Dato-DXd + D, showed promising responses. Updated results, including response duration (DoR), are reported. Patients (pts) with unresectable a/mTNBC eligible for 1L treatment were enrolled, regardless of PD-L1/TROP2 expression, and received Dato-DXd 6 mg/kg IV + D 1120 mg IV Q3W until progression or unacceptable toxicity. PD-L1, assessed by the VENTANA PD-L1 (SP263) Assay, was high if ≥10% of the tumor area was populated by PD-L1–expressing tumor or immune cells. Primary endpoints were safety and tolerability. Secondary endpoints included investigator-assessed ORR, PFS (RECIST v1.1), and DoR. As of 2 Feb 2023, 62 pts received Dato-DXd + D (29 ongoing). Median follow-up was 11.7 (range 2–20) months (mos). At baseline, median pt age was 53 years; 60% had visceral metastases; 87% had PD-L1–low expression. Confirmed ORR was 79% (95% CI, 67–88); 6 (10%) pts had complete and 43 (69%) had partial responses. Response to treatment was irrespective of PD-L1 expression level. Median DoR was 15.5 mos (95% CI, 9.9–not calculable [NC]). Median PFS was 13.8 mos (95% CI, 11–NC). Nausea and stomatitis were the most common adverse events (AEs; 40 [65%] each). Any Grade (G) 3/4 AEs occurred in 35 (57%) pts and serious AEs in 14 (23%). Low rates of anemia (9 [15%]), diarrhea (8 [13%]), and neutropenia (3 [5%]) occurred. Adjudicated treatment-related interstitial lung disease/pneumonitis occurred in 3 (5%) pts (2 G2; 1 G1). No deaths due to treatment-related AEs occurred. 10 (16%) pts discontinued any study drug due to AEs. No new safety signals were reported. Dato-DXd combined with D continues to demonstrate manageable safety and compelling high, durable response rates in 1L a/mTNBC. Further investigation is warranted. Translational data analysis is ongoing. Funding: AstraZeneca/Daiichi Sankyo.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zhawenchang发布了新的文献求助10
刚刚
xxy发布了新的文献求助10
1秒前
周舟发布了新的文献求助10
1秒前
laoying关注了科研通微信公众号
1秒前
第五彧轩发布了新的文献求助10
2秒前
苹果绝义完成签到,获得积分10
2秒前
2秒前
2秒前
小蘑菇的应助被魔幻雨梅采纳,获得10
2秒前
Bonnienuit发布了新的文献求助50
2秒前
科研通AI6.2的应助被kun采纳,获得10
2秒前
Dcientist完成签到,获得积分10
3秒前
Orange的应助被安详念蕾采纳,获得10
3秒前
3秒前
明天过后完成签到,获得积分10
4秒前
peng发布了新的文献求助10
4秒前
满意血茗完成签到,获得积分20
4秒前
Camellia完成签到,获得积分10
4秒前
5秒前
华仔的应助被132采纳,获得10
5秒前
小陈发布了新的文献求助10
5秒前
5秒前
summit完成签到,获得积分10
5秒前
6秒前
13103688576完成签到,获得积分10
6秒前
传奇3的应助被FQYJ采纳,获得20
6秒前
武淑晴发布了新的文献求助10
6秒前
情怀的应助被dahafei采纳,获得10
7秒前
7秒前
浮绡完成签到 ,获得积分10
7秒前
小芳子完成签到 ,获得积分10
7秒前
7秒前
xuanxuan完成签到 ,获得积分10
7秒前
在水一方的应助被丙队长采纳,获得10
7秒前
7秒前
开心的盼波完成签到 ,获得积分10
8秒前
Tt完成签到,获得积分20
8秒前
Camellia发布了新的文献求助10
8秒前
8秒前
哈哈完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8154161
求助须知:如何正确求助?哪些是违规求助? 9550701
关于积分的说明 21700590
捐赠科研通 7743260
什么是DOI,文献DOI怎么找? 3425651
关于科研通互助平台的介绍 2550861
邀请新用户注册赠送积分活动 2469363